The UK Health Security Agency (UKHSA) and The Pirbright Institute have launched a new collaboration to develop vaccines against henipavirus, a genus of
viruses that includes Nipah virus.
Funded by the Medical Research Council, this research aims to develop a vaccine that provides cross protection against the whole genus, addressing the threat of
outbreaks from new or emerging henipaviruses and strengthening epidemic preparedness.
Scientists at UKHSA will evaluate the protective efficacy of vaccines developed by The Pirbright Institute by using use a model of Nipah virus disease, which
mimics the infection in humans.
Professor Isabel Oliver, chief scientific officer at UKHSA, stated that the study would improve understanding of henipaviruses and enhance efforts to protect
health from this "current and future global health threat."
"The work will also make a vital contribution to the 100 Days Mission - an important initiative to make sure the world is better prepared for the next pandemic
by accelerating the development of diagnostics, therapeutics and vaccines," he added.
Otrivine brings the world's first air-purifying "Air Bubble" to Glasgow in a bid to raise awareness of the devastating effect of air pollution on children's health.
Air pollution is considered the world's largest environmental health threat, with 93 per cent of children breathing polluted air every day according to the World Health Organisation (WHO).
The Air Bubble, launched to help bring this invisible crisis to the top of the agenda, is an educational architecture, using biotechnology to purify the air.
The nose is one of our first lines of defence when it comes to filtering out particle pollutants from the air we breathe. As a world leader in nasal health, Otrivine is demonstrating how innovative nature-based technology can expand the functionality of our nose to 'clean' the air we breathe in polluted urban environments.
Two new medications which fight drug-resistant superbugs could soon become available to NHS patients in England after the National Institute for Health and Care Excellence (NICE) said they offered value for money.
NICE said Cefiderocol and ceftazidime-avibactam will be the first antimicrobial drugs to be made available as part of a subscription-style payment model that incentivises research and development of antimicrobials by testing new approaches to evaluating and paying for them.
As part of part of a project with the NHS and the Department of Health and Social Care, the new payment model is designed to address the growing threat posed by antimicrobial resistance - a serious global problem - which develops when the pathogens that cause infection evolve to make antibiotics and other antimicrobial
drugs less effective or stop them from working altogether.
The Association of the British Pharmaceutical Industry (ABPI) has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics.
On Tuesday (12 April), NICE published a draft guidance to tackle antimicrobial resistance under which two new antimicrobial drugs - cefiderocol and ceftazidime-avibactam - became the first to be made available as part of the UK's innovative subscription-style payment model.
Commenting on the announcement of the new draft guidance, Richard Torbett, chief executive of the ABPI, said: "This is an important milestone in the UK's global leadership on AMR. Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face.
"To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.
A second Global Covid-19 Summit will be held virtually next month for countries to discuss efforts to end the pandemic and prepare for future health threats, according to a joint statement on Monday (April18).
"The emergence and spread of new variants, like Omicron, have reinforced the need for a strategy aimed at controlling Covid-19 worldwide," the White House said in a news release with the Group of Seven and Group of 20 nations.
The announcement comes amid a surge of Covid-19 cases around the world prompted by easily transmissible variants of the virus.
China's most populous city, Shanghai, is trying to return to normal after a nearly three-week shutdown, which, along with wider China curbs, are taking a toll on the world's No. 2 economy.
The summit will build on efforts and commitments made at the first global summit in September, including getting more people vaccinated, sending tests and treatments to highest-risk populations, expanding protections to health care workers and generating financing for pandemic preparedness, the statement said.
The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial
resistance (AMR) research.
Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to
support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant
infections and prevent death and disease across the world.
In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global
access to - new antibiotic treatments against major global health priorities.
The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell
participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for
2023-2025, as part of Minister Quince's address at the WHA.
Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR
Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.
Recent uptake of COVID-19 vaccine booster doses in Europe has been "rather disappointing," an official said on Thursday (November 24), amid concerns that
protection against severe cases of the disease could weaken during the winter.
The European average rate of re-vaccination, or receiving booster doses, was only 29 per cent in the groups of people considered to be at highest risk, such as
the elderly and immunocompromised.
"It is of concern that those most at risk of hospitalisation or severe COVID are not adequately protected," the European Medicines Agency's head of health threats
and vaccines strategy, Marco Cavaleri, told a news briefing.
Though there have not been major increases in COVID-19 case rates in recent weeks, Cavaleri said that could change during the colder winter months.
The Royal Pharmaceutical Society (RPS) Scotland the BMA's Scottish GP Committee has called for improvements to the pharmacotherapy service.
The joint statement released by the organisations on Friday (13 January), has recognised that much progress has been made but states that further improvements are
needed to fully maximise the benefits of the service.
It highlighted the need for better use of skill mix, including more clearly defining roles and responsibilities; improved IT enablers to reduce administrative burden;
and further developing a tandem model of working comprising hubs with in-practice activity
The two organisations state that inadequate funding and workforce shortages are a real threat to the pharmacotherapy service.
They have urge Scottish Government to reconsider its recent decision to reduce funding for training pharmacy technicians.
Clare Morrison, RPS Director for Scotland, said: "In the statement, we stress that the use of pharmacists' clinical skills must be maximised.
Being able to access high-quality healthcare at the times you need it most is vital. Regardless of whether this is a simple check-up, a medical review or
complex surgery, having a suitable healthcare package designed according to your medical needs will be beneficial in the long run.
The NHS has recently come under significant strain. Factors such as an increase in the number of patients, reduced funding and increased life expectancy have led to
long waiting times and limited treatments.
As a result, more individuals are now seeking private healthcare which, while it may be more expensive, offers faster and more effective treatment. Here we'll discuss
some of the main benefits of private healthcare and why it is becoming the ideal choice for healthcare in 2023.
Reduced waiting times
One of the main issues faced by the NHS is waiting times, with some patients being made to wait up to a year for routine hospital care. Currently, ambulance services
and A&E units are under unprecedented pressure and it is estimated that hundreds of deaths each week are associated with admission delays.
Understaffing has been a chronic issue in recent years in the NHS and is a major threat to the welfare of patients. This has been one of the major concerns that has
led to nurses and ambulance staff taking strike action. As nurses and hospital workers are put under higher strain, they are more likely to make mistakes, which
could well lead to patients coming into harm and making a claim.
Opting for private healthcare guarantees that you are able to access your appointments, surgeries and treatments much quicker, with some flexibility offered to align
with your lifestyle. The capacity to bypass the painfully long waiting times ensures you receive the necessary medical attention much sooner and could prevent the
emergence of other health complications.
Researchers at at an Australian university have developed a new form of antibiotic that can be swiftly re-engineered to avoid resistance to dangerous superbugs.
The antibiotic, which was developed by PhD candidate Priscila Cardoso and major supervisor Dr Celine Valery from RMIT's School of Health and Biosciences, has a basic
architecture that allows it to be generated quickly and cheaply in a lab. The antibiotic, Priscilicidin, has tiny amino acid building blocks that allow it to be
tailored to combat various types of antimicrobial resistance.
With the World Health Organization calling antimicrobial resistance "one of the top ten global public health threats facing humanity", developing new antibiotics has
become more urgent than ever.
Professor Charlotte Conn, one of Cardoso's PhD supervisors, said given that urgency, Priscilicidin was an exciting breakthrough for public health.
Priscilicidin is a type of antimicrobial peptide. These peptides are produced by all living organisms as the first defence against bacteria and viruses.
British health officials on Wednesday (September 28) warned that increased circulation of flu and a resurgence in Covid-19 could lead to a difficult winter that
increases pressure on the already stretched NHS.
Warnings over a possible "twindemic" of Covid-19 and flu have been issued each winter since the start of the coronavirus pandemic in early 2020, but Covid
restrictions that limited social contact have meant flu levels stayed low.
However, the government ended coronavirus restrictions earlier this year, meaning that social contact rates have returned to near pre-pandemic norms while immunity
to flu is relatively low.
The UK Health Security Agency (UKHSA) said that given the risk it was important those eligible took up vaccines against Covid and flu.
"There are strong indications we could be facing the threat of widely circulating flu, lower levels of natural immunity due to less exposure over the last three
winters and an increase in Covid-19 circulating," said Susan Hopkins, chief medical advisor at UKHSA.
The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the
next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June).
The paper details how a financially sustainable VPAS can support widened medicines access to patients.
VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI).
The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues.
Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to
26.5 per cent.
"The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme,
data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the
association.
The Pharmacists' Defence Association has reported an increase in the number of pharmacists calling its advice line to inform about the incidences of violence and intimidation from protesters opposing the Covid-19 vaccination programme.
The association noted that such incidents have become more common with protesters "gaining entry to premises in groups and trying to disrupt Covid-19 vaccinations from taking place."
In many cases, pharmacists, staff, and members of the public have been subjected to verbal threats, causing distress and anxiety among those working to deliver the vaccination programme in a safe environment.
The PDA reminded that employers, having a contract with the NHS for the Covid-19 vaccinations, have a duty to keep their staff safe whilst at work.
The General Pharmaceutical Council (GPhC) standards for pharmacy premises also carry a duty to ensure the safety of staff and the public receiving services on those premises.
Lloyds Pharmacy's closure of all its 1,300 branches will wake-up the ministers and NHS officials to the reality of community pharmacy sector in England has
reached crisis point, expressed Nigel Swift Managing Director of Rowlands pharmacy and Deputy Managing Director of PHOENIX UK.
On Friday, The SUN reported that the UK's second largest pharmacy provider - is allegedly in the process of selling its entire estate of 1300 branches. Lloyds
Pharmacy will no longer be a High Street presence following its decision to put all its pharmacy branches at the risk of closure. In January it has announced to
close its 237 Sainsbury-based pharmacies.
Nigel highlighted the fact that community pharmacy is struggling due to insufficient government funding and immense pressures on GPs and A&E departments - an ongoing
issue which poses a very real threat to the sector.
Commenting on the announcement, he said: "It's not just Lloyds - an independent analysis by Ernst & Young estimated that 75% of community pharmacies will be in
financial distress in the coming years. £750 million has been taken out of the English contract due to inflation since it began."
Genomic sequencing allowed the world to track new coronavirus variants throughout the pandemic. Now British researchers plan to use it to better understand a
host of other respiratory pathogens, from influenza to respiratory syncytial virus (RSV).
The work is aimed at shedding more light on known threats and, potentially, emerging ones, the team at the Wellcome Sanger Institute, working with the UK Health
Security Agency, said.
The world has never had access to the kind of real-time information for these viruses that scientists obtained on SARS-CoV-2 through sequencing millions of genomes,
Ewan Harrison, head of the new Respiratory Virus and Microbiome Initiative, told reporters on Monday.
That includes granular detail on how they transmit as well as how they evolve in the face of the human immune response.
"We hope that by expanding our ability to sequence these viruses routinely, we can build upon the work that's going on COVID, and hopefully supercharge research
efforts to understand the transmission of these viruses, but also to help develop new treatments and vaccines," Harrison said.
The National Pharmacy Association (NPA) is distributing new campaign materials to pharmacies across England this week to empower them to advocate for fair
funding in the forthcoming general election.
These include campaign posters, stickers, postcards for patients to send to MPs and petition materials.
By supplying these resources, the NPA aims to boost its cross-sector #SaveOurPharmacies campaign and help pharmacies raise local and national awareness of the
funding crisis that is forcing pharmacies to close at the rate of 10 a week.
NPA chief executive Paul Rees said: "Pharmacies are under crushing financial pressure. We want to help them join our efforts to raise the profile of the funding
crisis and make the public and politicians fully aware of the threat to our much-loved pharmacy network.
In a collaborative effort to combat the escalating threat of antimicrobial resistance (AMR), UWE Bristol and Bedminster Pharmacy have secured grant funding
from the UKRI Regional Innovation Fund (RIF) for a groundbreaking 4-month project.
This initiative aims to revolutionise antimicrobial stewardship (AMS) practices at the community pharmacy level, addressing the pressing need for evidence-based
approaches in tackling AMR.
With antibiotic misuse contributing significantly to the rise of AMR, the project underscores the vital role of community pharmacies in promoting responsible
antibiotic use.
Mr Ade Williams, Superintendent Pharmacist at Bedminster Pharmacy, emphasised the significance of this endeavour, stating:
Community Pharmacies are set to significantly upgrade their digital security as the mandatory rollout of NHSmail Multi-Factor Authentication (MFA) begins
this month (August 1, 2024).
In an announcement by the Community Pharmacy England (CPE), pharmacies are urged to make the updates following a period of optional MFA implementations that began
in late 2023.
According to the new requirements, the mandatory update is crucial for protecting patient privacy and the integrity of their health records.
By adding an extra layer of security beyond the standard email address and password, MFA helps safeguard against unauthorised access.
This is especially vital in light of increasing cyber threats targeting healthcare systems.
Cyberattacks, including ransomware, can compromise patient records and disrupt care delivery, making robust security measures essential.
The introduction of MFA aims to curb these risks.
According to cybersecurity research, MFA can prevent up to 80 per cent data breaches and block over 99.9 per cent of compromised accounts.
At the recent 'Locum Matters' online event held on June 25, 2024, members of the Pharmacists' Defence Association (PDA) discussed critical issues facing
locum pharmacists, with a disturbing trend taking center stage: employers pressuring locum pharmacists to accept lower rates under the threat of potential pharmacy
closures.
The event, organised in response to feedback from PDA locum members, addressed a range of significant topics including training for the recent Pharmacy First
Services, respect for professional autonomy, and the need for adequate rest breaks.
However, the issue of rate pressure and pharmacy closures was a focal point.
Several locum pharmacists reported that some employers were leveraging the possibility of pharmacy closures to coerce them into working for lower pay.
This unethical practice has raised alarm within the locum community, highlighting the precarious working conditions many face.
Trauma can turn our world upside down, leaving scars that are not always visible. Whether it's a car accident, the loss of a loved one, or a natural disaster,
serious trauma can deeply affect our mental health. Coping with such events is crucial not only for our immediate well-being but also for our long-term recovery.
In this post, we'll explore six psychological tips to help you deal with the aftermath of a traumatic event. By integrating these strategies into your life, you can begin to heal and find a path forward. Keep on reading to learn more!
Understanding Trauma
What Is Trauma?
Trauma is an emotional response to a distressing event or series of events. These events can overwhelm an individual's ability to cope, leading to feelings of
helplessness, disorientation, and intense fear. Trauma is not limited to physical injuries; it can deeply affect emotional and mental health.
How Trauma Affects the Brain
When we experience trauma, our brain goes into survival mode. The amygdala, responsible for detecting threats, becomes overactive. Meanwhile, the prefrontal cortex,
which helps with rational thinking, can become underactive. This imbalance can lead to heightened anxiety, flashbacks, and difficulty concentrating.